Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme

Cancer

Volumn 119, Issue 4, 2013, Pages 814-824

  Zhang, Wei ^a   Zhang, Jing ^b   Yan, Wei ^a   You, Gan ^a   Bao, Zhaoshi ^a   Li, Shouwei ^a   Kang, Chunsheng ^d   Jiang, Chuanlu ^e   You, Yongping ^f   Zhang, Yuxiang ^g   Chen, Clark C ^h   Song, Sonya Wei ^c   Jiang, Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^c PEKING UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e HARBIN MEDICAL UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; glioblastoma; microRNA; prognosis; risk score

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CHINA; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DATABASE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAMPLE; SCORING SYSTEM; SURVIVAL PREDICTION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ASIAN CONTINENTAL ANCESTRY GROUP; CENTRAL NERVOUS SYSTEM NEOPLASMS; COHORT STUDIES; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MICRORNAS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84873342453     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27826     Document Type: Article

References (25)

1. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64: 6892-6899.
2. Ludwig JA, Weinstein JN,. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005; 5: 845-856.
3. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-866.
4. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103: 2257-2261.
5. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs down-regulate large numbers of target mRNAs. Nature. 2005; 433: 769-773.
6. Blenkiron C, Miska EA,. MicroRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum Mol Genet 16 (spec no 1): R106-R113, 2007.
7. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353: 1793-1801.
8. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189-198.
9. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297: 1901-1908.
10. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299: 425-436.
11. Chen J, Lozach J, Garcia EW, et al. Highly sensitive and specific microRNA expression profiling using BeadArray technology [serial online]. Nucleic Acids Res. 2008; 36: e87.
12. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of 6 genes. N Engl J Med. 2004; 350: 1828-1837.
13. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008; 13: 48-57.
14. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002; 20: 1375-1382.
15. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
16. Srinivasan S, Patric IR, Somasundaram K,. A ten-microRNA expression signature predicts survival in glioblastoma [serial online]. PLoS One. 2011; 6: e17438.
17. Bast RC Jr, Hortobagyi GN,. Individualized care for patients with cancer-a work in progress. N Engl J Med. 2004; 351: 2865-2867.
18. Ramaswamy S,. Translating cancer genomics into clinical oncology. N Engl J Med. 2004; 350: 1814-1816.
19. Miska EA, Alvarez-Saavedra E, Townsend M, et al. Microarray analysis of microRNA expression in the developing mammalian brain [serial online]. Genome Biol. 2004; 5: R68.
20. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334: 1351-1358.
21. Conti A, Aguennouz M, La Torre D, et al. miR-21 and 221 up-regulation and miR-181b down-regulation in human grade II-IV astrocytic tumors. J Neurooncol. 2009; 93: 325-332.
22. Shi L, Cheng Z, Zhang J, et al. Hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008; 1236: 185-193.
23. Chen G, Zhu W, Shi D, et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep. 2010; 23: 997-1003.
24. Zhi F, Chen X, Wang S, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer. 2010; 46: 1640-1649.
25. Slaby O, Lakomy R, Fadrus P, et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 2010; 57: 264-269.